Zobrazeno 1 - 10
of 148
pro vyhledávání: '"Markku, Korpela"'
Autor:
Tuija Väänänen, Katriina Vuolteenaho, Hannu Kautiainen, Riina Nieminen, Timo Möttönen, Pekka Hannonen, Markku Korpela, Markku J Kauppi, Kari Laiho, Oili Kaipiainen-Seppänen, Riitta Luosujärvi, Tea Uusitalo, Toini Uutela, Marjatta Leirisalo-Repo, Eeva Moilanen, NEO-RACo Study Group
Publikováno v:
PLoS ONE, Vol 12, Iss 8, p e0183294 (2017)
YKL-40, a chitinase-like glycoprotein associated with inflammation and tissue remodeling, is produced by joint tissues and recognized as a candidate auto-antigen in rheumatoid arthritis (RA). In the present study, we investigated YKL-40 as a potentia
Externí odkaz:
https://doaj.org/article/6049803f74e6424a87fd85ebba81496f
Autor:
Janne Laine, Jukka Lumio, Salla Toikkanen, Mikko J Virtanen, Terhi Uotila, Markku Korpela, Eila Kujansuu, Markku Kuusi
Publikováno v:
PLoS ONE, Vol 9, Iss 1, p e85457 (2014)
An extensive drinking water-associated gastroenteritis outbreak took place in the town of Nokia in Southern Finland in 2007. 53% of the exposed came down with gastroenteritis and 7% had arthritis-like symptoms (joint swelling, redness, warmth or pain
Externí odkaz:
https://doaj.org/article/5e3c3d8284744cfcb833082c6d64e5e7
Publikováno v:
Clinical Rheumatology. 34:1485-1488
Autoreactive B cells infected by Epstein-Barr virus (EBV) are suspected to be involved in the etiology of various human chronic autoimmune diseases. This motivated us to study the relationship between peripheral blood EBV load at baseline and treatme
Autor:
Marja, Pertovaara, Markku, Korpela
Publikováno v:
Clinical and experimental rheumatology. 35(4)
Publikováno v:
Rheumatology. 54:1103-1113
Objective Many cytokines involved in RA activate the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathways. Therapeutic drugs that inhibit these pathways are being developed for RA. To investigate disease-related alteratio
Autor:
Markku Korpela, M. Pertovaara
Publikováno v:
Rheumatology. 53:927-931
Objective. A European League Against Rheumatism (EULAR) SS disease activity index (ESSDAI) and a patient-reported index (ESSPRI) have recently been developed and validated. In our previous study the ESSDAI correlated significantly with serum b2 micro
Autor:
Markku Korpela, Markku J Kauppi, Kari Laiho, Hannu Kautiainen, M Hakola, Anna Karjalainen, Vappu Rantalaiho, Pekka Hannonen, Timo Möttönen, Marjatta Leirisalo-Repo, Ritva Peltomaa, Oili Kaipiainen-Seppänen, Leena Laasonen
Publikováno v:
Annals of the Rheumatic Diseases. 73:1954-1961
Objective To study whether adding initial infliximab to remission-targeted initial combination-DMARD treatment improves the long-term outcomes in patients with early rheumatoid arthritis (RA). Methods Ninety-nine patients with early, DMARD-naive RA w
Publikováno v:
Rheumatology. 52:1999-2003
Objectives To investigate the use of DMARDs and biologic treatments and disease activity in patients with JIA referred to the adult rheumatology clinic and to provide further information regarding the need for long-term rheumatologic care. Methods We
Publikováno v:
Clinical and experimental rheumatology. 35(2)
Autor:
Adrian, Levitsky, Marius C, Wick, Timo, Möttönen, Marjatta, Leirisalo-Repo, Leena, Laasonen, Markku, Korpela, Ronald F, van Vollenhoven, Vappu, Rantalaiho
Publikováno v:
Clinical and experimental rheumatology. 34(6)
Predicted versus observed radiographic progression in early rheumatoid arthritis (POPeRA) was applied to demonstrate how various treatment modalities affect and potentially minimise radiographic progression over time.The POPeRA method utilises the ba